Medicilon(SH:688202) Tong Hua Shun Cai Bao·2025-04-21 12:05Financial Performance - The company reported a basic earnings per share of -2.47 yuan for 2024, a significant decline of 850% compared to -0.26 yuan in 2023 [1] - The net profit for 2024 was -3.31 billion yuan, representing a drastic decrease of 903.03% from -0.33 billion yuan in 2023 [1] - The operating revenue decreased by 24.01% to 10.38 billion yuan in 2024, down from 13.66 billion yuan in 2023 [1] - The return on equity was -14.24% in 2024, a sharp decline from -1.75% in 2023 [1] - The net asset per share decreased by 14.75% to 15.89 yuan in 2024, compared to 18.64 yuan in 2023 [1] Shareholder Structure - The top ten unrestricted shareholders collectively hold 66.849 million shares, accounting for 49.64% of the circulating shares, with an increase of 10.4409 million shares compared to the previous period [2] - The largest shareholder, Chen Jinzhan, holds 16.3628 million shares, representing 12.15% of the total share capital, with no change in holdings [3] - Other significant shareholders include Chen Jianhuang (12.94 million shares, 8.94%), Chen Chunlai (7.9571 million shares, 5.91%), and Wang Guolin (6.3916 million shares, 4.75%), all of whom maintained their positions [3] Dividend Policy - The company has decided not to distribute dividends or increase capital through stock distribution [2]